Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine.
Orexin/hypocretin neurons of the lateral hypothalamus/perifornical area project to a diverse array of brain regions and are responsive to a variety of psychostimulant drugs. It has been shown that orexin neurons are activated by systemic nicotine administration suggesting a possible orexinergic contribution to the effects of this drug on arousal and cognitive function. The basal forebrain and paraventricular nucleus of the dorsal thalamus (PVT) both receive orexin inputs and have been implicated in arousal, attention and psychostimulant drug responses. However, it is unknown whether orexin inputs to these areas are activated by psychostimulant drugs such as nicotine. Here, we infused the retrograde tract tracer cholera toxin B subunit (CTb) into either the basal forebrain or PVT of adult male rats. Seven to 10 days later, animals received an acute systemic administration of (-) nicotine hydrogen tartrate or vehicle and were euthanized 2h later. Triple-label immunohistochemistry/immunofluorescence was used to detect Fos expression in retrogradely-labeled orexin neurons. Nicotine increased Fos expression in orexin neurons projecting to both basal forebrain and PVT. The relative activation in lateral and medial banks of retrogradely-labeled orexin neurons was similar following basal forebrain CTb deposits, but was more pronounced in the medial bank following PVT deposits of CTb. Our findings suggest that orexin inputs to the basal forebrain and PVT may contribute to nicotine effects on arousal and cognition and provide further support for the existence of functional heterogeneity across the medial-lateral distribution of orexin neurons.
Pasumarthi
Ravi K
RK
Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, Columbia, SC 29208, USA.
Fadel
Jim
J
D000818:Animals; D002772:Cholera Toxin / Q000008:administration & dosage / Q000378:metabolism; D004525:Efferent Pathways / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005455:Fluorescent Antibody Technique / Q000379:methods; D005917:Globus Pallidus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D007274:Injections, Intraperitoneal; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D020644:Midline Thalamic Nuclei / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009479:Neuropeptides / Q000008:administration & dosage / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D000068797:Orexins; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013377:Substantia Innominata / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D013788:Thalamus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D000068797:Orexins; D016760:Proto-Oncogene Proteins c-fos; D009538:Nicotine; D002772:Cholera Toxin